Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Buyout numbers
View:
Post by CaseyL on Oct 23, 2023 2:22pm

Buyout numbers

Could we fetch 7 billion in a buyout? I would really like to hear Notables take an it.
Comment by Noteable on Oct 23, 2023 3:26pm
I've already provided my take, particularly since ONCY has targeted the metastatic pancreatic, breast,  and colorectal cancer markets with a biomarker driven biological in the form of  pelareorep, which is eligible for 13 years of FDA market exclusivity on each indication approved. And the markets for these cancers are significant as already stated.
Comment by canadafan on Oct 23, 2023 4:12pm
A buy out number? Depens on when. The closer we get to approval the higher the price goes. Once phase 3 start is announced. Regardless of how the busness model is structured.  THAT wlll be a HUGE validation of the machine moving forward. Predictions of mine? Based on analysts assesments etc  Assuimimg a quick buy-out, being next few months, pre-partnership. That would be $1.5 billion ...more  
Comment by fox7mf on Oct 23, 2023 4:17pm
Hey Lee, welcome. Don't mind Canadafan, he's like ALWAYS wrong:) As for cranky Noteable, he's on record predicting a number between $10b- $15b...fingers crossed;)
Comment by Azzak34 on Oct 23, 2023 4:19pm
Don't worry about Fox's passive aggressive tone, he's "like" always a complete tool. 
Comment by canadafan on Oct 23, 2023 4:23pm
Hey if it comes in at $10-$15 billion, Id be quite happy to be wrong. I gave my justifications for the numbers. I well apreciate there are those who think that my $1.5 - $5 billion is silly low. others think  Silly  high. Regardless, we will only know , when it happens, not before. I have been a shareholder of 6-7 companies that were bought out. Trust me: They were all a surprise ...more  
Comment by Buckhenry on Oct 23, 2023 4:27pm
I have blocked most of the forever pumpers but I can just hear them now. They went ape sh!t on stocktwits so I would figure the same on this site. I will wait for NR before I go buy that yacht. 
Comment by Azzak34 on Oct 23, 2023 4:39pm
You don't have shares here or you wouldn't constantly FUD against it.  What's your name on Stocktwits? You FUDDING over there too? 
Comment by fox7mf on Oct 23, 2023 5:49pm
In any event, let's make up the 40 plus cents lost last week before we talk about buyouts. Good day, but we are still 50% down from the 52 week high.
Comment by Noteable on Oct 23, 2023 7:03pm
With Roche's US$ 7.1 Billion acquisition price for an experimental drug in ulcerative colitis,  ONCY's buy out potential is certainly north of there, for reasons already provided including Big Pharma's looming patent cliff and Roche's strategy around Tecentriq.
Comment by venture009 on Oct 23, 2023 8:22pm
https://www.ft.com/content/99d8bdb4-b854-411f-b3b4-fcb6f94f8292 This article is interesting from the perspective that Roche has not had much success when it comes to aquisitions and PIII, and the market has punished them. They will be very cautious. Should we expect an imminent offer. The $billion question. Let's hope they have had enough experience with pela to make an offer. 
Comment by Noteable on Oct 23, 2023 8:48pm
The global ulcerative colitis market was valued at USD $7.1 billion in 2020, and is projected to reach USD$10.8 billion by 2030. - so growth in this market segment appears to have matured, yet Roche decided to acquire Telavant for USD $7.1billion, presumably in part, on the strength of biomarker data in Riovants Phase2b study.   Conversely, the global pancreatic cancer market was valued ...more  
Comment by Noteable on Nov 23, 2023 3:03pm
With Roche's US$ 7.1 Billion acquisition price for an experimental drug in ulcerative colitis,  ONCY's buy out potential is certainly north of there, for te following reasons including Big Pharma's looming patent cliff and Roche's strategy around Tecentriq. The global ulcerative colitis market was valued at USD $7.1 billion in 2020, and is projected to reach USD$10.8 ...more  
Comment by CaseyL on Nov 23, 2023 4:51pm
Thank you for your input Noteable. Happy Thanksgiving, American time. if you're not Canadian. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities